Motley Fool
SpaceX Could IPO in June at a $1.75 Trillion Valuation. Here Is 1 Stock to Buy Before It Does.
SpaceX is reportedly eyeing a public offering as early as June that would value the company at a staggering $1.75 trillion, making it one of the largest IPOs in history. The listing would unlock significant downstream opportunities for companies already embedded in its supply chain and technology ecosystem. Savvy investors are moving now, targeting AI-linked plays positioned to surge once the SpaceX halo effect kicks in.
Read article →Motley Fool
The Stock Market Sounds an Alarm for the First Time in 25 Years. Here Is What History Says the S&P 500 Will Do in 2026.
The S&P 500's Shiller CAPE ratio has hit its highest valuation level in over 25 years, a historically reliable warning signal for stretched equity markets. The last time readings climbed this high was during the dot-com bubble, a period that preceded significant market losses. Investors watching the 2026 outlook would be wise to weigh what this rare valuation extreme has meant for forward returns in the past.
Read article →Motley Fool
Nvidia Investors Just Got Incredible News from CEO Jensen Huang: 2 Highlights from GTC
Nvidia's annual GTC developer conference opened with a series of major announcements from CEO Jensen Huang, signaling the company's continued dominance in the AI hardware race. Huang's keynote delivered concrete product and partnership details that reinforced investor confidence in the chipmaker's growth trajectory. For shareholders already riding one of the market's most remarkable runs, the news adds fresh momentum heading into the rest of 2025.
Read article →Motley Fool
Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data
CytomX Therapeutics jumped sharply after releasing promising Phase 1 data showing early efficacy in colorectal cancer treatment. The results offered a rare bright spot for the clinical-stage biotech, even as investors contended with disappointing quarterly financials and concerns about how long the company's cash reserves will last. The tension between clinical progress and fiscal fragility will likely keep the stock volatile in the near term.
Read article →Get this delivered every morning
Join thousands of readers who get the world's most important stories, curated daily.
Start reading free →